Glenmark launches nasal spray for allergic rhinitis

Glenmark Pharmaceuticals has announced the launch of RyaltrisAZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark, being one of the leaders in the respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, costeffective treatment option in the country. Mumbaibased Glenmark is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg. Ryaltris-AZ nasal spray is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with allergic rhinitis in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red and watery eyes.